RecruitingPhase 2

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

United States80 participantsStarted 2025-10-30

Plain-language summary

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2 × the upper limit of normal (ULN) or total bilirubin \>2 × ULN (except participants with Gilbert Syndrome).
✕. Creatinine levels: \>2 mg/dL (\>177 μmol/L)

What they're measuring

Number of Participants at Week 12 Achieving Peak Esophageal Intraepithelial Eosinophil Count <15 eos/hpf.

Timeframe: Week 12

Trial details

NCT IDNCT06851559

SponsorPhathom Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Phathom Medical Information

1-888-775-PHAT (7428) medicalinformation@phathompharma.com

View on ClinicalTrials.gov More Eosinophilic Esophagitis trials